HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas.

Abstract
A retargeted measles virus strain MV-GFP-H(AA)-scEGFR was generated by engineering the MV-NSe Edmonston vaccine strain to incorporate both CD46 (Y481A) and signaling lymphocyte activation molecule (SLAM) (R533A) ablating mutations in the hemagglutinin protein in combination with the display of a single-chain antibody against epidermal growth factor receptor (EGFR) at the C terminus of hemagglutinin. The unmodified MV-GFP virus was used as a positive control. Specificity of the EGFR retargeted virus was demonstrated in non-permissive Chinese hamster ovary (CHO) cells stably transfected to express either the natural receptors CD46 or SLAM or the target receptors EGFR and EGFRvIII. In vitro, the retargeted virus had potent antitumor activity against EGFR- or EGFRvIII-overexpressing primary glioblastoma multi-forme (GBM) cell lines that was comparable to the activity of the unmodified MV-GFP virus. Intratumoral administration of MV-GFP-H(AA)-scEGFRvIII in orthotopic GBM12 xenografts resulted in tumor regression, as demonstrated by bioluminescence imaging and significant prolongation of survival, that was comparable to the effect of the unmodified strain. In contrast to MV-GFP, central nervous system administration of the targeted MV-GFP-H(AA)-scEGFR virus in measles replication-permissive Ifnar(ko) CD46 transgenic mice resulted in no neurotoxicity. In conclusion, EGFR-retargeted measles virus strains have comparable therapeutic efficacy to the unmodified virus in glioma cells overexpressing EGFR or EGFRvIII in vivo and in vitro, and improved therapeutic index, a finding with potential translational implications in glioma virotherapy.
AuthorsGeorgia Paraskevakou, Cory Allen, Takafumi Nakamura, Paula Zollman, C David James, Kah Whye Peng, Mark Schroeder, Stephen J Russell, Evanthia Galanis
JournalMolecular therapy : the journal of the American Society of Gene Therapy (Mol Ther) Vol. 15 Issue 4 Pg. 677-86 (Apr 2007) ISSN: 1525-0016 [Print] United States
PMID17299404 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Antigens, CD
  • CD46 protein, human
  • Membrane Cofactor Protein
  • Receptors, Cell Surface
  • Recombinant Proteins
  • Green Fluorescent Proteins
  • Signaling Lymphocytic Activation Molecule Family Member 1
  • ErbB Receptors
Topics
  • Animals
  • Antigens, CD (genetics)
  • CHO Cells
  • Cell Line, Tumor
  • Chlorocebus aethiops
  • Cricetinae
  • Cricetulus
  • ErbB Receptors (genetics)
  • Gene Expression
  • Genes, erbB-1
  • Genetic Engineering
  • Genetic Therapy (methods)
  • Glioma (genetics, immunology, therapy)
  • Green Fluorescent Proteins (genetics)
  • Humans
  • Measles virus (genetics)
  • Membrane Cofactor Protein (genetics)
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Mutation
  • Neoplasm Transplantation
  • Receptors, Cell Surface (genetics)
  • Recombinant Proteins (genetics)
  • Signaling Lymphocytic Activation Molecule Family Member 1
  • Transplantation, Heterologous
  • Vero Cells

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: